Hawkeye Bio

Hawkeye Bio is a private, early-stage diagnostics company founded in 2020 and headquartered in Cambridge, Massachusetts, with additional operations in Los Angeles and Ireland. The company's core innovation is a graphene-based biosensor platform that detects disease-specific enzyme activity rather than just biomarker concentration, aiming for high sensitivity and cost-effectiveness in screening for cancer and inflammatory diseases. Its most advanced asset is the ProLung blood test for early lung cancer detection, which has demonstrated promising clinical performance metrics in early data. Hawkeye is positioned in the high-growth liquid biopsy market, targeting significant unmet needs in cancer screening compliance and accessibility.

Patented nano-scale graphene biosensor platform that measures the activity levels of disease-specific enzymes (e.g., proteases) from non-invasive liquid biopsy samples (blood, saliva, urine).

Hawkeye operates in the highly competitive early cancer detection liquid biopsy market, competing against companies using multi-omics, methylation, and NGS-based approaches (e.g., Grail, Guardant Health, Freenome). Its differentiation lies in its lower-cost, enzyme-activity-based biosensor platform, but it must prove superior or comparable clinical utility to gain market share.